Union Korea Pharm Co., Ltd. (KOSDAQ:080720)
South Korea · Delayed Price · Currency is KRW 2,725.00
-310.00 (-10.21%)
At close: Oct 11, 2024
Union Korea Pharm Revenue
In the year 2025, Union Korea Pharm had annual revenue of 36.38B KRW, down -29.06%. Union Korea Pharm had revenue of 6.48B in the quarter ending December 31, 2025, with 64.76% growth.
Revenue
36.38B
Revenue Growth
-29.06%
P/S Ratio
0.54
Revenue / Employee
219.15M
Employees
166
Market Cap
19.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.38B | -14.90B | -29.06% |
| Dec 31, 2024 | 51.28B | -11.89B | -18.82% |
| Dec 31, 2023 | 63.17B | 1.88B | 3.06% |
| Dec 31, 2022 | 61.29B | 12.99B | 26.89% |
| Dec 31, 2021 | 48.30B | -2.08B | -4.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 99.01B |
| ChoA Pharmaceutical Co., LTD. | 59.31B |
| WooGene B&G | 54.76B |
| CXI Healthcare Technology Group | 54.16B |
| Seoul Pharma | 52.15B |
| Kwangdong Healthbio | 38.10B |
| Daesung Microbiological Labs. | 25.99B |
| BIFIDO | 19.68B |